GLP-1 wars: Wegovy maker challenges knock-off weight loss drug companies

Novo Nordisk sued telehealth provider Hims & Hers on Feb. 9 alleging patent infringement after Hims announced plans to sell a compounded oral version of Wegovy for $49/month, prompting FDA warnings and HHS referral to DOJ; Hims subsequently dropped its pill plans but continues to sell injectables. Novo cited internal testing finding impurities up to 86% in compounded injectables and 75% in compounded pills, while both Novo and Eli Lilly have cut cash prices (Novo cut many injectables to $349/month from $499; Lilly cut Zepbound 2.5 mg to $299 and 5 mg to $399) as oral Wegovy prescriptions hit ~50,000 weekly and competition from Lilly’s orforglipron looms. The dispute raises regulatory and IP risk for compounding pharmacies and telehealth sellers, while reinforcing pricing and market-share dynamics among incumbent pharma players.

Analysis

Market structure: Novo (NVO) is the primary beneficiary of aggressive IP enforcement and FDA pressure on compounders — removing lower-cost compounded alternatives should restore pricing power for branded oral and injectable GLP-1s and push cash buyers back to channels like manufacturers and big-box retailers (Costco). Competing branded entrants (Lilly’s orforglipron expected in April) cap long-term pricing but near-term exclusivity for oral Wegovy and enforcement actions create a 3–12 month window of stronger gross margins and volume capture. Telehealth/compounders (HIMS, independent compound pharmacies) are the clear losers if litigation and FDA actions scale; revenue pools of the cash market (~tens of millions monthly prescriptions implied by 50k weekly oral fills) will reflow to regulated channels.

Risk assessment: Tail risks include a court invalidating key Wegovy formulation patents (low-probability, high-impact) or an adverse FDA finding/recall tied to impurity claims that could crater demand and spike legal liabilities within 30–90 days. Timeline: immediate market moves on FDA enforcement (days–weeks), litigation and injunctions play out over 6–18 months, Lilly approval/entry in April is a near-term pricing catalyst. Hidden dependencies include employer formulary expansion (Mercer: 49% large employers covered in 2025) and API supply from third-party manufacturers that could flip dynamics quickly.

Trade implications: Favor long NVO exposure with asymmetric option leverage (6–12 month call spreads) to capture enforcement-driven reversion of cash customers; size 2–3% portfolio long equity or equivalent option exposure. Pair trade idea: long NVO vs short HIMS (HIMS) to isolate IP/regulatory wins; consider buying 3–6 month HIMS puts if volatility cheapens. Add modest long in COST (1–2%) to capture retail distribution flow-through and pharmacy sales; trim if Lilly gains approval or if employer coverage expands meaningfully.

Contrarian angles: Consensus underestimates that enforcement could be net-positive for branded players if it accelerates normalization of quality perceptions and channels — branded share could rise by 5–15% in cash markets over 6 months. Conversely, the market may be underpricing the risk of rapid commoditization if courts narrow patent scope or if payors force price concessions; watch for historical parallels to Humira biosimilar litigation where early suits preserved pricing for years. Unintended consequence: aggressive crackdowns could push some patients to black-market sources, harming long-term demand and reputational capital for incumbents.

Key Decisions for Investors

• Establish a 2–3% long position in NVO (equity) with a paired 6–12 month call spread (buy ~5% ITM/ATM call, sell ~20% OTM call) to cap cost and capture upside from reduced compounding competition; if NVO rises >20% in 3 months, trim to 1–1.5%.
• Enter a pair trade: long NVO (2%) and short HIMS (ticker HIMS) equal notional (1–1 ratio) over a 3–9 month horizon; hedge with buying 3–6 month HIMS puts (strike ~5–10% OTM) sized to cover 50% of short position.
• Initiate a 1–2% long position in COST to capture incremental in-store pharmacy sales and traffic; target +8–12% upside over 6–12 months and set a stop-loss at -12% or if branded channel volumes fall >15% versus consensus.
• Use FDA calendar and legal milestones as explicit triggers: if Lilly’s orforglipron is approved in April, reduce NVO equity exposure by 30% within 2 weeks; if courts issue injunctions against compounders within 90 days, add 25–50% to NVO option exposure.